比索洛尔联合替格瑞洛对急性心肌梗死患者PCI术后Galectin-3、CEACAM 1水平的影响  

Effect of bisoprolol combined with ticagrelor on levels of Galectin-3 and CEACAM1 in patients with acute myocardial infarction after PCI

作　　者：江涛[1] 徐艳娜 张亚云[3] JIANG Tao;XU Yan-na;ZHANG Ya-yun(First Department of Cardiology,Baoding Second Central Hospital,Baoding,Hebei,072750,China)

机构地区：[1]保定市第二中心医院心内一科,河北保定072750 [2]河北省第八人民医院 [3]石家庄市第八医院

出　　处：《心血管康复医学杂志》2024年第4期420-425,共6页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：河北省2020年度医学科学研究课题计划(20200170)。

摘　　要：目的:探究比索洛尔联合替格瑞洛对急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后半乳糖凝集素-3(Galectin-3)、癌胚抗原相关细胞黏附分子1(CEACAM1)水平的影响。方法:选择2019年5月~2021年6月在我院接受PCI术的140例AMI患者。根据抛硬币法分为对照组70例和联合组70例,两组均使用阿司匹林,对照组在此基础上使用替格瑞洛,联合组使用替格瑞洛联合比索洛尔,均治疗2周。比较两组治疗前后Galectin-3、CEACAM1、血清N末端B型利钠肽前体(NT-proBNP)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)、内皮素-1(ET-1)、丙二醛(MDA)水平,治疗效果以及不良反应情况。结果:与对照组治疗后比较,联合组Galectin-3[(34.67±2.34)ng/L比(28.54±1.92)ng/L]、CEACAM1[(229.64±17.36)pg/ml比(175.54±11.97)pg/ml]、NT-proBNP[(196.49±20.83)ng/L比(103.46±16.35)ng/L]、TNF-α[(5.68±0.72)mg/L比(3.23±0.57)mg/L]、ET-1[(59.47±4.74)ng/L比(45.29±3.84)ng/L]、MDA[(8.42±0.96)μmol/L比(5.03±0.46)μmol/L]水平均显著降低,NO水平[(72.34±5.69)μmol/L比(92.16±6.61)μmol/L]显著升高(P均<0.001)。联合组总有效率(94.29%比75.71%)显著高于对照组(P=0.002),而不良反应发生率(1.43%比14.29%)显著低于对照组(P=0.005)。结论:替格瑞洛联合比索洛尔可以显著降低AMI患者Galectin-3、CEACAM1水平,提高患者的治疗有效率且安全性良好,值得推广应用。Objective:To investigate the effect of bisoprolol combined with ticagrelor on levels of Galectin-3,carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1)in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods:A total of 140 AMI patients underwent PCI in our hospital from May 2019 to June 2021 were selected.According to coin-toss method,they were divided into control group(n=70)and combined group(n=70).Both groups received aspirin,control group received ticagrelor on this basis,while combined group received ticagrelor combined bisoprolol on the basis.Both groups were treated for two weeks.Levels of Galectin-3,CEACAM1,serum N terminal pro B-type natriuretic peptide(NT-proBNP),tumor necrosis factor-α(TNF-α),nitric oxide(NO),endothelin-1(ET-1)and malondialdehyde(MDA)before and after treatment,therapeutic effect and incidence of adverse reactions were compared between two groups.Results:Compared with control group after treatment,combined group showed significant reductions in levels of Galectin-3[(34.67±2.34)ng/L vs.(28.54±1.92)ng/L],CEACAM1[(229.64±17.36)pg/ml vs.(175.54±11.97)pg/ml],NT-proBNP[(196.49±20.83)ng/L vs.(103.46±16.35)ng/L],TNF-α[(5.68±0.72)mg/L vs.(3.23±0.57)mg/L],ET-1[(59.47±4.74)ng/L vs.(45.29±3.84)ng/L]and MDA[(8.42±0.96)μmol/L vs.(5.03±0.46)μmol/L],and significant increase in NO level[(72.34±5.69)μmol/L vs.(92.16±6.61)μmol/L](P<0.001 all).Total effective rate(94.29%vs.75.71%)of combined group was significantly higher than that of control group(P=0.002),while incidence rate of adverse reactions(1.43%vs.14.29%)was significantly lower than that of control group(P=0.005).Conclusion:Ticagrelor combined with bisoprolol can significantly reduce levels of Galectin-3 and CEACAM1,improve the therapeutic effective rate with good safety in AMI patients,which is worthy of promotion and application.

关 键 词：心肌梗死 比索洛尔 替格瑞洛 半乳糖凝集素3 

分 类 号：R542.22[医药卫生—心血管疾病]